• Larimar Therapeutics Chief Development Officer Gopi Shankar purchased 5,000 shares of Common Stock at $2.7098 per share.
• The purchase increased his direct holdings to 81,443 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458830), on November 12, 2026, and is solely responsible for the information contained therein.